Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, pursuant to the Answer of 11 November 2014 to Question 213785, whether the cost effectiveness modelling of the PPV programme developed by Public Health England will be made publicly available when it is presented to the pneumococcal disease sub-committee of the Joint Committee on Vaccination and Immunisation in spring 2015.

The Joint Committee on Vaccination and Immunisation (JCVI) Pneumococcal Sub-committee will meet in spring 2015. At this meeting of the Pneumococcal Sub-committee members will begin their review of the impact and cost-effectiveness of the pneumococcal polysaccharide vaccine (PPV) immunisation programme.

The mechanism by which the JCVI undertakes economic evaluations, including cost-effectiveness analyses, are described in the JCVI Codes of Practice. The JCVI may, when appropriate, publish additional information on parameters used in cost-effectiveness models in the minutes of Sub-Committee and main JCVI meetings. This applies particularly to parameters for which there may be a substantial degree of uncertainty. The JCVI does not make public details of cost-effectiveness modelling where this would compromise the Department of Health's vaccine procurement process or disclose information provided in confidence to the JCVI by vaccine manufacturers. Additional modelling information is likely to be made publicly available through peer-reviewed publications.